用抗TNF药物治疗排卵管炎患者的管理,这些患者发展出脱线性疾病 - 一个案例系列
Abel Hamdan1, Sumit Sharma1, Kimberly Baynes1
1Cole Eye Institute, Cleveland Clinic, 2022 E 105th St I Building, Cleveland, OH, 44106, USA.
Journal of ophthalmic inflammation and infection
|July 30, 2024
概括
抗瘤坏死因子 (Anti-TNF) 药物可以在紫外线炎患者中引起罕见的神经并发症. 早期识别和管理对于有利的结果至关重要,在停止抗TNF治疗后可以实现疾病控制.
科学领域:
- 眼科医生 眼科 眼科
- 神经学 神经学
- 免疫学 免疫学 免疫学
背景情况:
- 抗瘤坏死因子 (Anti-TNF) 药物对慢性非传染性脑膜炎有效.
- 罕见的神经系统并发症,包括脱髓化疾病,可以发生在抗TNF治疗.
- 对并发性脑膜炎和神经疾病的管理策略尚未得到充分确立.
研究的目的:
- 在接受抗TNF药物治疗的非传染性脑膜炎患者中发现神经复发症的病例.
- 描述这些具体案例的管理和结果.
- 了解抗TNF治疗后眼睛和神经疾病的过程.
主要方法:
- 追溯的观察案例系列.
- 电子医疗记录 (EMR) 对394名接受抗TNF治疗的非传染性脑膜炎患者的审查.
- 在接受抗TNF治疗时,识别出现新的神经症状的患者,并审查随后的治疗和结果.
主要成果:
- 在抗TNF治疗期间,发现了5名患者出现神经症状.
- 记录了随后的脱髓化诊断,急性治疗和长期疗程.
- 所有五名患者在停用抗TNF药物后大约三年实现了非活性疾病状态.
结论:
- 与抗TNF药物相关的罕见神经症状和脱髓化疾病可能会对患者的治疗结果产生负面影响.
- 通过详细的神经病史和成像进行早期识别对于管理这些并发症至关重要.
- 停止抗TNF治疗,加上替代性免疫抑制剂,可以导致疾病控制.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
124
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
124
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
149
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
149
Inflammatory Bowel Disease IV: Pharmacological Management
124
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
124
T Cell Types and Functions
967
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
967
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
110
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
110
Myasthenia Gravis: Overview and Treatment
1.3K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.3K


